clinical trial · NCT04779242
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Community-acquired PneumoniaBacterial PneumoniaOmadacyclineMoxifloxacin
brief summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
started
Feb 25, 2021
primary completion
Mar 27, 2024
completion
Mar 27, 2024
last updated
Apr 9, 2025
official title
A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol